Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2018 Feb 1;14(2):378-385.
doi: 10.1080/21645515.2017.1405882. Epub 2017 Dec 20.

Report from enhanced safety surveillance of two influenza vaccines (Vaxigrip and Intanza 15 μg) in two European countries during influenza season 2016/17 and comparison with 2015/16 season

Anne Laure Chabanon  1 , Hélène Bricout  1 , Céline Ballandras  2 , Audrey Souverain  3 , Timothy David Caroe  4 , Karina M Butler  5
Affiliations
Observational Study

Report from enhanced safety surveillance of two influenza vaccines (Vaxigrip and Intanza 15 μg) in two European countries during influenza season 2016/17 and comparison with 2015/16 season

Anne Laure Chabanon et al. Hum Vaccin Immunother. .

Abstract

Passive enhanced safety surveillance (ESS) was implemented in the United Kingdom and in the Republic of Ireland for Vaxigrip and Intanza 15 µg influenza vaccines during the 2016/17 influenza season. Lessons learned during 2015/16 ESS implementation were integrated and applied towards the current ESS. The primary objective was to estimate the reporting rates of suspected adverse reactions (ARs) occurring within 7 days of vaccination with Vaxigrip or Intanza 15 µg. For Vaxigrip (N = 962), 17 vaccinees (1.8%) reported 59 suspected ARs (6.1%) within 7 days of vaccination. For Intanza 15 µg (N = 1000), 21 vaccinees (2.1%) reported 101 (10.1%) suspected ARs within 7 days of vaccination. No obvious pattern in the type of suspected ARs or their frequency was observed for either vaccine. None of the frequencies of suspected ARs were above the 2015/16 ESS frequencies for Vaxigrip, whereas for Intanza 15 µg only one AR (oropharyngeal pain) crossed the historical threshold. There was no change in reactogenicity and data was consistent with the safety profiles of the two vaccines. The passive ESS experience gained from season to season will help to contribute to a sustainable safety surveillance system of seasonal influenza vaccines early in the season.

Keywords: Inactivated influenza vaccine; The Republic of Ireland; United Kingdom; influenza; passive surveillance; vaccines and immunization.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Percentage of Vaxigrip safety report cards distributed during the 2015/16 influenza season and the 2016/17 influenza season by age group. aThe total number of safety report cards distributed was 1012 and 962 for the 2015/16 influenza season and the 2016/17 influenza season, respectively.
See this image and copyright information in PMC

References

    1. Vaccines against influenza WHO position paper. November 2012. Wkly Epidemiol Rec. 2012;87(47):461–76. PMID:23210147 - PubMed
    1. Pharmacovigilance Risk Assessment Committee (PRAC) [Internet] Interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU. London: European Medicines Agency (EMA) 2014. [Accessed 29May2017]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guidelin...
    1. Bricout H, Chabanon AL, Souverain A, Sadorge C, Vesikari T, Caroe T. Passive enhanced safety surveillance for Vaxigrip and Intanza 15 μg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16. Euro Surveill. 2017;22(18):30527. doi:10.2807/1560-7917.ES.2017.22.18.30527. PMID:28494843 - DOI - PMC - PubMed
    1. Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber P, Pless RP, Mootrey G, Ellenberg SS, et al. . Surveillance for safety after immunization: vaccine adverse event reporting system (VAERS) – United States, 1991–2001. MMWR Surveill Summ. 2003;52(1):1–24. PMID:12825543 - PubMed
    1. Alguacil Ramos AM, Lluch Rodrigo JA, Portero Alonso A, Martín Ivorra R, Pastor Villalba E. [Variability in the reporting of adverse reactions to the pandemic and seasonal influenza vaccine: seasons 2009–2010 and 2010–2011. Valencian community, Spain]. Rev Esp Salud Pública. 2012;86(3):241–51. - PubMed

Publication types

Substances